

Presentation of the pediatric diabetes study tomorrow Wednesday

NextCell Pharma AB (“NextCell”) has invited Professor Per-Ola Carlsson to present study design and rationale for the pediatric study, ProTrans-Young. The trial, recently approved, is a phase I / II study with a total of 66 patients with newly diagnosed type-1 diabetes.

The presentation will be broadcasted tomorrow, Wednesday April 28, at 14:00. Afterwards, there is an opportunity to ask questions to Professor Carlsson and NextCell's CEO and CSO.

<https://youtu.be/kE4POLMIXWA>.

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Sofia Fredrikson, CFO

Tel: 08-735 5595

E-mail: info@nextcellpharma.com

Hemsida: www.nextcellpharma.com

LinkedIn: <https://www.linkedin.com/company/15255207/>

Twitter: <https://twitter.com/NextCellPharma>

About NextCell Pharma AB

NextCell is a Phase II cell therapy company with the lead candidate ProTrans™, for the treatment of type-1 diabetes. Focus is on taking ProTrans™ to market approval via a phase III study. Furthermore, NextCell operates Cellaviva, Scandinavia's largest stem cell bank for family-saving of stem cells from umbilical cord blood and umbilical cord tissue with permission from the Health and Social Care Inspectorate. FNCA Sweden AB is appointed Certified Adviser, +46(0)8-528 00 399, info@fnca.se.